The share of PROMOMED shares in free circulation will increase due to the repayment of structural bonds by transferring shares of the Company

April 30, 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries– the "Group") announces the upcoming repayment of structural bonds in the amount of more than 1.6 billion rubles.

The bonds will be redeemed on April 30, 2026 by transferring PROMOMED ordinary shares to investors for an amount corresponding to the total issue volume. Settlements are expected to be completed within maturity day, and more than 450 bondholders will become shareholders of the Company.

After the transfer of shares is completed, the free-float[i] PROMO CODE will increase from 6.7% to 8.5%, and the Company's short-term debt will decrease by 1.6 billion rubles.

The Company will continue to implement measures aimed at increasing shareholder value. The increase in free-float, as well as the recent involvement of a market maker, may contribute to a further increase in the liquidity of the Company's shares and is consistent with the Company's medium-term goal of moving from the second quotation list of the Moscow Stock Exchange to the first.

Increasing the liquidity of shares is part of the Company's consistent work with the capital market and minority shareholders. Earlier, in the interests of minority shareholders, the Company made changes to the Dividend Policy[ii]. The current recommendation is The Board of Directors is considering the General Director's decision on the payment of dividends.

About the deal

Following the placement in April 2025, the Company raised more than 1.6 billion rubles to continue financing its investment program aimed at developing innovative medicines.

For the purposes of settlement of the transaction, 60 shares of the Company were used per bond, and the bond placement price was set at RUB 25,119.00 (the "Initial Price"). The discount was not applied to the placement of bonds, which was aimed at protecting the interests of the current minority shareholders of PROMOMED.

The weighted average price used for calculations at the maturity date of the instrument was higher than the Initial Price.

The structuring of the transaction, its support during the period of circulation of bonds and their repayment was provided by the Lekap team.

The issuer of the bonds was the specialized financial company SFO CADMIUM CREDIT LLC under the management of the management company FOCUS Management.

---

[i] The share of shares in free circulation.

[ii] According to Adjusted net profit is the net profit for the period adjusted for the amount of capitalized expenses in respect of fixed assets and non–profit assets (payments in connection with acquisition, creation, modernization, reconstruction and preparation for the use of fixed assets and payments in connection with the acquisition and creation of intangible assets) and depreciation on capitalized expenses in respect of fixed assets and IA.

About the Company
PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.

The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of Limitation of liability This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers to purchase any securities,
• as part of such offers or invitations,
• advertising of securities in the Russian Federation or other jurisdictions,
• an offer to purchase medicines,
• advertising of medicines,
• by encouraging or recommending transactions,
• and is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this message does not imply investment advice.ovation (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page: href="https://e-disclosure.ru/portal/company.aspx?id=38533">https://e-disclosure.ru/portal/company.aspx?id=38533 The information contained in this communication may include estimates and other forward-looking statements regarding intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.